Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ: ORKA )

19.01 -0.97 (-4.85%)
Official Closing Price Updated: 4:15 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 133,976
Open 19.65
Bid (Size) 18.00 (2)
Ask (Size) 24.00 (28)
Prev. Close 19.98
Today's Range 18.81 - 19.87
52wk Range 18.20 - 31.13
Shares Outstanding N/A
Dividend Yield 8.49%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
From Oruka Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-25.45%
-25.45%
1 Month
+1.71%
+1.71%
3 Month
-20.36%
-20.36%
6 Month
-25.45%
-25.45%
1 Year
-25.45%
-25.45%

More News

Read More
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics to Present at Multiple November Investor Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces $200 Million Private Placement
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.